A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant
Dammerman, R.; Kim, S.; Adera, M.; Schwarz, A.
Psychopharmacology Bulletin 47(4): 36-40
2017
ISSN/ISBN: 0048-5764 PMID: 28936007 Document Number: 692689
Document emailed within 1 workday
Related Documents
Llorca, P-M.; Sacchetti, E.; Lloyd, K.; Kissling, W.; Medori, R. 2008: Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months International Journal of Clinical Pharmacology and Therapeutics 46(1): 14-22De Souza, A.; Strober, B.E.; Merola, J.F.; Oliver, S.; Franks, A.G. 2012: Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study Journal of Drugs in Dermatology: Jdd 11(10): 1224-1226
Fearon, K.C.; Falconer, J.S.; Ross, J.A.; Carter, D.C.; Hunter, J.O.; Reynolds, P.D.; Tuffnell, Q. 1996: An open-label phase I/Ii dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate Anticancer Research 16(2): 867-874
Semmanaselvan, K.; Mukaddam, Q.I.; Naik, M. 2015: An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Reflux Disease Journal of the Association of Physicians of India 63(7): 27-32
Jutasompakorn, P.; Kongpatanakul, S.; Pongnarin, P.; Sathirakul, K.; Chatsiricharoenkul, S. 2015: Comparative Fasting Bioavailability of 2 Cilostazol Formulations in Healthy Thai Volunteers: An Open-Label, Single-Dose, Randomized, 2-Way Crossover Study Journal of the Medical Association of Thailand 98(9): 910-915
Li, C.-H.; Shi, L.; Zhan, G.-L.; Rao, S.-Z.; Zhang, H. 2013: A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder European Review for Medical and Pharmacological Sciences 17(16): 2136-2140
Cullis, P.A.; O'Brien, C.F.; Truong, D.D.; Koller, M.; Villegas, T.P.; Wallace, J.D. 1998: Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients Advances in Neurology 78: 227-230
Yokota, S.; Imagawa, T.; Nishikomori, R.; Takada, H.; Abrams, K.; Lheritier, K.; Heike, T.; Hara, T. 2017: Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase IIi pivotal study in Japanese patients Clinical and Experimental Rheumatology 35 Suppl 108(6): 19-26
Saple, D.G.; Torsekar, R.G.; Pawanarkar, V.; Wali, V.; Ravichandran, G.; Dhanalakshmi, U.R.; Dongre, N.; Ballary, C.; Desai, A. 2003: Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: a multicentric, open label, phase IIi study Indian Journal of Dermatology Venereology and Leprology 69(6): 396-400
Gordon, J.; Udeh, U.; Doobay, K.; Magro, C.; Wildman, H.; Davids, M.; Mersten, J.N.; Huang, W.-T.; Lyman, S.; Crow, M.K.; Spiera, R.F. 2014: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial Clinical and Experimental Rheumatology 32(6 Suppl 86: S
Chen, B.A.; Blithe, D.L.; Muraguri, G.R.; Lance, A.A.; Carr, B.R.; Jensen, J.T.; Kimble, T.D.; Murthy, A.S.; Schreiber, C.A.; Thomas, M.A.; Walsh, T.L.; Westhoff, C.; Burke, A.E. 2019: Acceptability of the Woman's Condom in a phase IIi multicenter open-label study Contraception 99(6): 357-362
Schweizer, E.; Clary, C.; Weise, C.; Rickels, K. 1988: An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant Psychopharmacology Bulletin 24(1): 195-197
Goldberg, H.L.; Finnerty, R. 1988: An open-label, variable-dose study of WY-45,030 (venlafexine) in depressed outpatients Psychopharmacology Bulletin 24(1): 198-199
Zaenglein, A.L.; Shamban, A.; Webster, G.; Del Rosso, J.; Dover, J.S.; Swinyer, L.; Stein, L.; Lin, X.; Draelos, Z.; Gold, M.; Thiboutot, D. 2013: A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris Journal of Drugs in Dermatology: Jdd 12(6): 619-625
Gottlieb, A.B.; Matheson, R.T.; Menter, A.; Leonardi, C.L.; Day, R.M.; Hu, C.; Schafer, P.H.; Krueger, J.G. 2013: Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase Ii open-label study Journal of Drugs in Dermatology: Jdd 12(8): 888-897
Cohen, J.L.; Dayan, S.H. 2006: Botulinum toxin type a in the treatment of dermatochalasis: an open-label, randomized, dose-comparison study Journal of Drugs in Dermatology: Jdd 5(7): 596-601
Besner, J.G.; Leclaire, R.; Band, P.; Meloche, S.; Deschamps, M.; Mailhot, S.; Moisan, R.; Diorio, G. 1985: Single-dose pharmacokinetic study of 13-cis-retinoic acid in man Cancer Treatment Reports 69(3): 275-277
Draelos, Z.ë D.; Feldman, S.R.; Butners, V.; Alió Saenz, A.B. 2013: Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study Journal of Drugs in Dermatology: Jdd 12(1): E1-E6
Heffernan, M.P.; Smith, D.I.; Bentley, D.; Tabacchi, M.; Graves, J.E. 2007: A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus Journal of Drugs in Dermatology: Jdd 6(3): 310-314
O'Dwyer, P.J.; Hudes, G.R.; Walczak, J.; Schilder, R.; LaCreta, F.; Rogers, B.; Cohen, I.; Kowal, C.; Whitfield, L.; Boyd, R.A. 1992: Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule Cancer Research 52(24): 6746-6753